Hojuhn Song, Ph.D.
Co-Founder and Chief Executive Officer
Hojuhn is a biopharmaceutical leader and executive who has successfully led several R&D teams in start-up, and global large-pharmaceutical settings. His teams have progressed multiple novel agents through development in oncology, immune disorder, and neurodegeneration.
Before founding Pinetree Therapeutics, Inc, Hojuhn was a project team leader for novel target discovery in Functional Genomics and Developmental Molecular Pathway at Novartis Institute for Biomedical Research and successfully generated multiple clinical candidates in multiple therapeutic areas.
Hojuhn earned a Ph.D. in Genetics and Neurobiology at Oregon State University and completed a post-doctoral fellowship at Novartis AG. He received M.S in Genetics and a B.Sc. In Biology from Chungnam National University, S. Korea.
Director of Strategic Finance
Mia is a seasoned corporate finance professional. Prior to joining PineTree In February 2021, Mia was the director of finance at Massachusetts Immigrant & Refugee Advocacy Coalition, finance manager at Genosco and director of the US operations at AbClon. She is also a long-time advocate for Korean-American entrepreneurship ecosystem in Boston area since 2009 when she worked as the business attaché for the Korean Consulate.
Initially trained to be an engineer, she is a Certified Management Accountant and earned her MBA from Sungkyunkwan Graduate School of Business in collaboration with MIT Sloan School.
Ranajoy (Ron) Sarkar Ph.D., MBA
Director of Business Development
Ron is a Pharmaceutical and Biotechnology Executive with 16+ years of experience spearheading Product Development and Business Development.
He has worked in large, publicly-traded Fortune 500 (Allergan, Teva, Pfizer and GlaxoSmithKline) and mid-sized (Forest Laboratories) Pharmaceutical companies as well as Biotech (Assembly Biosciences) in multiple Leadership roles with expanding responsibilities. He has contributed to both Business Development as well as Drug Product Development activities. He has experience of deal teams from both buy and sell side, and contributed to the decision-making of $2B+ transactions including M&A, licensing and co-development opportunities. He has led Global Product Development teams in R&D as well as Commercial Manufacturing that developed drugs in all stages of development, many of which are now FDA-approved, including several blockbusters.
Ron holds an MBA degree from The Wharton School, University of Pennsylvania and a Ph.D. degree from the College of Pharmacy’s Pharmaceutical and Biomedical Sciences, University of Georgia.